Abstract
Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer, and its mortality rate is the highest among gynecological malignancies. Despite numerous factors being linked to the prognosis of EOC, the impact of ovarian laterality has received limited attention. In this study, we comprehensively examined the effects of laterality (left-right and bilateral-unilateral) on the incidence and prognosis of EOC, with a particular focus on different subtypes. By utilizing a large clinical database, we found that laterality differences primarily existed between unilateral and bilateral cases in terms of both incidence and prognosis. Specifically, unilateral tumour development was predominantly observed in patients with clear cell, endometrioid, and mucinous ovarian cancer subtypes, while bilateral involvement was more common in serous ovarian cancer. Laterality differences, reflecting disparities between the left and right sides, were primarily observed in various stages of the overall population and within specific EOC subtypes. Specifically, significant differences in EOC incidence between the left and right sides at different stages were observed in the overall population, as well as in clear cell, endometrioid, and serous ovarian cancer subtypes. Although no significant differences in the incidence rate between the left and right sides were noted for mucinous ovarian cancer, the prognosis was substantially better on the right side compared to the left side. These findings underscore the importance of considering ovarian laterality, both in terms of left-right and bilateral-unilateral aspects, as a critical factor associated with the incidence and prognosis of EOC. Therefore, it should be taken into account in clinical practice, particularly in the context of different tumour stages and subtypes of EOC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Key R&D Program of China (2022YFC2704200,2022YFC2704201）
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at the web (https://seer.cancer.gov/seerstat/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
